Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
ASCO 2018: Latest developments in non-metastatic and metastatic castration-resistant prostate cancer

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.18
Views: 2722

Dr Neal Shore, Dr Simon Chowdhury, Prof Matthew Smith and Prof Boris Hadaschik

Dr Neal Shore is joined by Dr Simon Chowdhury, Prof Matthew Smith and Prof Boris Hadaschik at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

The discussion opens with comments on the day's poster sessions here at ASCO 2018, including genomic profiling of tumours from mCRPC patients, which gives promising findings.

Following this there is a discussion about the P3 SPARTAN trial, investigating Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC), led by Prof Smith.

Prof Hadaschik comments on the Phase 2 randomised cross-over trial of abiraterone prednisone (ABI P) vs enzalutamide (ENZ) which give 2nd line therapy results. He believes the results point towards no large difference between the drugs, and at this point in time it should be down do a discussion with the clinician and patient. The panel discuss this further in the context of their own work.

Dr Chowdhury comments on the Phase II randomised trial; Olaparib combined with abiraterone in patients with mCRPC, and describes why he believes some of the results were unexpected, and also discusses some of the toxicities.

This leads on to Cora Sternberg's randomised phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC) with comments from Prof Smith particularly highlighting the changes in toxicity as the dose increased.

The discussion ends with a roundup of the Australian study with Lutetium and PSMA Gallium, Prof Hadaschik gives a detailed overview and opinion.


Genomic profiling in mCRPC
SPARTAN trial and metastatic free survival
Abiraterone and prednisone vs enzalutamide 
PARP inhibitors for prostate cancer
Dosing of radium-233
Lutetium-177 PSMA testing

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation